Keyword: Karyopharm Therapeutics
A new partnership will test drug cocktails containing Karyopharm's new product Xpovio in cell samples from glioblastoma patients.
The FDA will now rule on multiple myeloma drug selinexor by early July, three months later than planned.
Karyopharm took a 15% dip as investors waited for a phase 2b update on selinexor in refractory multiple myeloma.
Biogen is paying $10 million upfront and committing to up to $207 million more in milestones to buy the IND-ready oral SINE compound.
Embattled biotech Karyopharm is looking to move past its recent trial setbacks, penning an expansion to its original 2014 partnership on machine-learning tech and risk-based monitoring techniques for its cancer tests.
Karyopharm has seen studies for its big hope selinexor placed on a partial clinical hold, meaning it can no longer recruit new patients, over the FDA’s demands for more safety details, but the company insists this is all down to paperwork errors.
A phase 2 trial of Karyopharm’s selinexor in patients with acute myeloid leukemia (AML) has been deemed destined to fail during an interim analysis.